mechanism and inhibition

OKatsumi MATSUZAKI<sup>1</sup>

<sup>1</sup>Kyoto Univ. Grad. Sch. of Pharm. Sci.

The abnormal aggregation of amyloid  $\beta$ -peptide (A $\beta$ ) and its deposition to neurons are closely related to the pathogenesis of Alzheimer's disease. We revealed a novel aggregation mechanism in lipid rafts. A $\beta$  recoginzes

Ganglioside cluster-mediated aggregation and cytotoxicity of amyloid beta-peptide: molecular

S22-3

and binds to ganglioside clusters formed by an increase in cholesterol level. The membrane-bound  $A\beta$  forms an  $\alpha$ -helix-rich structure at lower densities. At higher densities,  $A\beta$  undergoes a conformational transition to a  $\beta$ -sheet-rich structure that can serve as a seed for amyloid fibril formation. The amyloid fibrils are more toxic than those formed in solution, suggesting the existence of polymorphisims in amyloids.

Low molecular weight compound that can inhibit the aggregation process would be candidates for therapeutics

agents. We examined the effects of eight compounds on the raft-mediated amyloidgenesis by  $A\beta$ . These compounds are known to inhibit amyloidgenesis in solution, Among them, four componds exhibited inhibitory effects. The most potent nordihydroguaiaretic acid prevented  $A\beta$  from membrane binding by interacting with  $A\beta$  and raft membranes.  $A\beta$  formed small elongated particles instead of forming fibrils in the presence of the compound.

compound. < Selected papers > J Biol Chem 276, 24985 (2001); Biochemistry 41, 7385 (2002); J Mol Biol 371, 924 (2007); BBA 1768, 122 (2007); J Mol Biol 382, 1066 (2008).